Rubius Therapeutics to Announce First Quarter 2022 Financial Results
CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage…
Month: April 2022
Rhythm Pharmaceuticals to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022
BOSTON, April 26, 2022 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical…
SOTIO Initiates CLAUDIO-01 Trial with Antibody-Drug Conjugate SOT102 in Patients with Gastric and Pancreatic Cancer
CLAUDIO-01 is the first-in-human trial of SOT102, a CLDN18.2 (Claudin 18.2) targeting antibody-drug conjugate (ADC)…
89bio to Host Key Opinion Leader Webinar on Severe Hypertriglyceridemia (SHTG)
Webinar to feature presentations from Harold Bays, MD, and Deepak L. Bhatt, MD, MPH, on…
VBL Therapeutics Receives FDA Fast Track Designation for Ofra-Vec for the Treatment of Platinum-Resistant Ovarian Cancer
FDA grants Fast Track designation to facilitate development and expedite the review of therapies with…
OncoC4 Announces Fast Track Designation Granted by the U.S. FDA for ONC-392 Monotherapy in PD(L)1-Resistant NSCLC
A Phase 1b clinical trial of ONC-392 in PD(L)1-resistant NSCLC is currently underway ROCKVILLE, Md.,…
Athira Files Investor Presentation Highlighting Successful Execution of its Strategy and Highly Qualified Board and Leadership
Urges shareholders to vote “FOR” Athira’s highly qualified, independent director nominees – Joseph Edelman, John…
Optinose Announces Appointment of R. John Fletcher to the Board
YARDLEY, Pa., April 26, 2022 (GLOBE NEWSWIRE) — Optinose (NASDAQ:OPTN), a pharmaceutical company focused on…
Avadel Pharmaceuticals Provides Comment on Recent Trading Activity
DUBLIN, Ireland, April 26, 2022 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical…
TG Therapeutics to Participate in the B. Riley Securities’ 2022 Virtual Neuro & Ophthalmology Conference
Fireside chat scheduled for Thursday, April 28, 2022 at 12:30 PM ET NEW YORK, April…
Nephros Unveils New Branding and Website
Rebrand reflects an integrated approach to water safety, with expanded focus on customer solutions and educational…
iSpecimen Unveils Enhanced iSpecimen Marketplace Platform to Help Scientists More Efficiently Find Desired Biospecimens for Research
Enhanced iSpecimen Marketplace Search Interface iSpecimen’s enhanced Marketplace now enables more precise specimen matching through…
Iovance Biotherapeutics to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 5, 2022
SAN CARLOS, Calif., April 26, 2022 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a…
NexImmune Announces Preclinical Research Collaboration with Columbia University Irving Medical Center’s Herbert Irving Comprehensive Cancer Center
GAITHERSBURG, Md., April 26, 2022 (GLOBE NEWSWIRE) — NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company…
Corvus Pharmaceuticals to Host R&D Symposium on May 10, 2022 in New York
Company to host a webcast at 9:00am ET / 6:00am PT BURLINGAME, Calif., April 26,…
Chalice Brands Ltd. Celebrates Record Setting 420 Performance and Announces the Launch of Chalice Metaverse Cannabis Platform
PORTLAND, Ore., April 26, 2022 (GLOBE NEWSWIRE) — Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF)…
2 Out of 3 Women With Depression or Anxiety Say They’ve Reached Their “Breaking Point” Yet More than Half Wait a Year Before Seeking Treatment
Six in 10 of the women surveyed with depression or anxiety diagnosis say they have…
BioNTech to Report First Quarter 2022 Financial Results and Operational Update on May 9, 2022
Mainz, Germany, April 26, 2022 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the…
TELA Bio to Announce First Quarter 2022 Financial Results
MALVERN, Pa., April 26, 2022 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA”), a commercial-stage medical…
Amicus Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022
PHILADELPHIA, April 26, 2022 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD) today announced that the…